Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") on behalf of purchasers of Organon securities ...

Law Offices of Howard G. Smith reminds investors of the upcoming July 22, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Organon & Co. ("Organon" ...

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Organon & Co. ("Organon" or the "Company") (NYSE: OGN) securities between ...

Organon planned to prioritize debt reduction following the Company’s acquisition of Dermavant; and (3) as a result, Defendants’ positive statements about the Company’s business, operations ...

Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") on behalf of purchasers of Organon securities ...

In October 2024, Organon acquired Dermavant, a biopharmaceutical company focused on dermatological conditions, for $1.2 billion. According to the lawsuit, despite the increase in debt from the ...

Dermavant's phase 3 trials of tapinarof – PSOARING 1 and 2 – showed that around 40% of patients responded to treatment with clear or almost clear skin at 12 weeks, compared to 6% of a placebo ...

Notably, defendants concealed the high priority of Organon’s debt reduction strategy following the Company’s acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly ...

Notably, defendants concealed the high priority of Organon's debt reduction strategy following Organon's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. When ...

Notably, defendants concealed the high priority of Organon's debt reduction strategy following Organon's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend.